Immunotolerance induction in a pediatric hemophilic patient in Costa Rica
DOI:
https://doi.org/10.51481/amc.v60i3.1010Keywords:
hemophilia A, inhibitors, Immunotolerance, ITI, Costa RicaAbstract
Hemophilia A is an X - linked bleeding disorder. It can be treated with Factor VIII prophylaxis or on demand treatment. Most countries in the world use prophylaxis as it is less expensive than treating patients when they are bleeding. The production of factor VIII inhibitors is the most common and serious complication of the treatment. Immune tolerance induction (ITI) is the only option of treatment when patients develop inhibitors proven to be successful to eradicate this condition, therefore decreasing inhibitors and costs. A case of a successful immune tolerance induction with low doses of factor VIII (FVIII) in a pediatric patient with severe hemophilia A and FVIII inhibitors is presented. Even though inmunotolerance has been practice before in our country, a case like this has never been published.
Downloads
References
Maissaa J, Steven P. What is the role of an extended half life product in immune tolerance induction in a patient with severe hemophilia A and high - titer inhibitors?. Hematology Am Soc Hematol Educ Program. 2016; 648-649.
Angelika B, Denisa J, Anna M, Eva B, Tatiana P, Julia H, Et al. Inhibitors in Severe Hemophilia A: 25 year Experience in Slovakia. SeminThromb Hemost 2016;42:550-62
Ay Y, Ersin T, Yesim O, Hilkay KT, Dilek I, Gulcihan O, Ahmet K. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country. Blood coagul fibrinolysis 2015; 27: 729-731
K. Holstein, A. Batorova, M. Carvalho, K. Fijnvandraat, P. Holme, K.Kavakli, et al. Current View and outcome of ITI therapy - A change over time?. Thromb Res 2016; 148: 38-44.
Mizoguchi Y, Furue A, Kagawa R, Chijimatsu I, Tomioka K, Shimomura M. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin. Int J Hematol 2016;103:473-7
Lynn M. Extended half life factor VIII for immune tolerance induction in haemophilia. Haemophilia. 2016; 22:e552-e554.
A. Rocino, P.A Cortesi, L.Scalone, L.G. Mantovani, R.Creas, and A. Gringer. Immune tolerance induction in patients with haemophilia A and inhibitors: effectiveness and cost analysus in an European Cohort (the ITER Study). Haemophilia. 2016; 22:96-102.
K. Berger, D. Schopohl, D. Eheberg, G.Auerwald, K. Kurnik, and W.Schramm. Treatment of children with Severe Haemophilia A and Inhibitors: a health Economic Evaluation for Germany. Klin Padiatr. 2013;225:152-158
N. Ewing, C.Escuriola and W.Kreuz. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2015; 21: 358-364
Downloads
Published
Versions
- 2018-07-27 (2)
- 2018-07-27 (1)
Issue
Section
License
Copyright (c) 2018 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
